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364:1395–406.True Fractional Flow
Reserve of Left Main
Coronary Artery Stenosis
in the Presence of
Downstream Coronary
StenosesWith great interest I read the recent paper by
Fearon et al. (1) in which they assessed the impact of
downstream left anterior descending (LAD) or left
circumﬂex (LCX) coronary stenosis on the assessment
of fractional ﬂow reserve (FFR) of an left main coro-
nary artery (LMCA) stenosis. They concluded that if
the apparent FFR of the LMCA (FFRapp) is >0.85, the
true FFR of the LMCA (FFRtrue) is always >0.80. If
FFRapp is between 0.81 and 0.85 and the epicardial
FFR (FFRepi) is &0.45, then FFRtrue is &0.80 in some
cases.
However, these conclusions are not surprising.
These conclusions can be proven mathematically.
Bruyne et al. (2) previously described theoretical
equations that calculate the true FFR of individual
stenosis in a tandem lesion. Based on their study, an
equation that calculates FFRtrue in a bifurcation
lesion can be derived. When the downstream steno-
sis is located in the LAD, and n is deﬁned as the ratio
of microcirculatory resistances of the LCX to the
LAD, FFRtrue is calculated as per the following
Equation 1.
FFRtrue ¼
nFFRepi þ FFRapp
1þ n1 FFRapp  FFRepi
 (1)
The partial differentiation of FFRtrue with respect to
FFRepi is calculated as follows:
vFFRtrue
vFFRepi
¼ nðnþ 1Þ

1 FFRapp

1þ n1 FFRapp  FFRepi
2>0 (2)The above inequality in Equation 2 indicates that
the FFRtrue monotonically increases when FFRepi is
larger. Similarly, the partial differentiation of
FFRtrue with respect to FFRapp and n are calculated
as follows:
vFFRtrue
vFFRapp
¼ ðnþ 1Þ

nFFRepi þ 1

1þ n1 FFRapp  FFRepi
2>0 (3)
vFFRtrue
vn
¼

1 FFRapp

FFRepi  FFRapp

1þ n1 FFRapp  FFRe
2 < 0 (4)
The inequalities in Equations 2, 3, and 4 suggest
that FFRtrue increases with FFRepi and FFRapp, but
that it decreases with an increase in n. n is the ratio
of microcirculatory resistances of the LCX to the
LAD, which is usually considered approximately 2.
Thus, FFRtrue > 080 is always true when FFRapp is
>0.85, FFRepi is >0.45, and n ¼ 2. Similarly, Equation 1
suggests that when FFRapp is between 0.81 and 0.85
and the epicardial FFR (FFRepi) is&0.45, then FFRtrue
can be either larger or smaller than 0.80. These cal-
culations are completely in accordance with the
study results of Fearon et al. (1). Their study was well
designed and the results were reasonable, but it
lacked the understandings of the background mech-
anism. Another important limitation of their study is
that they only assessed the LMCA plus 1 downstream
stenosis and lacked the assessment of the LMCA plus
2 downstream stenoses both in the LAD and LCX,
which is also frequently encountered in clinical
practice. In the case of the LMCA plus 2 downstream
stenoses, FFRtrue is calculated as per Equation 5 when
the epicardial FFR of the LAD and LCX are deﬁned as
FFRLAD and FFRLCX.
FFRtrue ¼
nFFRLAD þFFRLCX
1 FFRapp FFRLCX
þn1FFRapp FFRLAD

(5)
I hope that the legitimacy of Equation 5 will be
assessed in the future clinical study.*Naritatsu Saito, MD
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1840–7.REPLY: True Fractional Flow Reserve of
Left Main Coronary Artery Stenosis in the
Presence of Downstream Coronary StenosesWe would like to thank Dr. Saito for his interest in our
study (1) evaluating the inﬂuence of a downstream
epicardial stenosis on the fractional ﬂow reserve
measurement of an intermediate left main stenosis
with the pressure wire positioned in the nondiseased
contralateral vessel. We agree with Dr. Saito that the
ﬁndings are in accordance with mathematical equa-
tions like the one he proposes and the one we have
previously published, which demonstrated our un-
derstanding of the background mechanism (2). Un-
fortunately, these equations and the even more
complex one proposed for the case in which both
downstream vessels are diseased suffer from the
major limitation that they assume the microvascular
resistance in each downstream vessel. Moreover, as
was the case with the equations proposed for evalu-
ating the individual fractional ﬂow reserve values of
serial stenoses (3,4), their complexity makes it un-
likely that a practicing interventional cardiologist will
apply them clinically. We are pleased that Dr. Saito’s
letter highlights the practical message of our paper,
that the effect of downstream epicardial disease on
the functional assessment of intermediate left
main disease with the pressure wire in the non-
diseased downstream epicardial vessel is small and
clinically irrelevant, unless the downstream disease is
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Balloons in Bifurcations
The Remaining Variable to Fit the
Perfect EquationWe have read with great interest and satisfaction
the elegant paper written by Kim et al. (1) and the
editorial by Abdel-Latif et al. (2); we want to
congratulate the authors on the original design of
these 2 trials. As occurs with chronic total occlu-
sions and left main disease, bifurcation lesions
represent a constantly debated issue in all the
meetings of Interventional Cardiology, and despite
the large number of trials and the different tech-
niques tested, there still exist unresolved aspects in
the treatment of this subset of patients. To date,
none of the dedicated stent platforms has shown
relevant advantages over the conventional drug-
eluting stents (DES) because of their higher pro-
ﬁle, the complexity of utilization, or the need for
additional stents, and although there is a general
agreement supported by previous trials that provi-
sional stenting is the best choice, there is still sig-
niﬁcant heterogeneity, and different techniques are
widely used, such as crush, T-stenting, modiﬁed T-
stenting, culotte, and a large list of the mentioned
dedicated stents and techniques. The data provided
by these 2 trials with 54% of second-generation DES
in the CROSS (Choice Of Optimal Strategy For
Bifurcation Lesions With Normal Side Branch) and
37% in the PERFECT (Optimal Stenting Strategy For
True Bifurcation Lesions) trials show us the best
paths to face against these challenging lesions in
the following years. Second-generation stents have
